Soltamox was and is still a joke. My guess is $10,000 revenue for quarter ending Dec 2012.
Soltamox was and is still a joke. My guess is $10,000 revenue for quarter ending Dec 2012. Back in the year 2006, I think it did about $40,000 a year. So $10,000 a quarter sounds about right.
Anyway, it depends on how Dara recognizes revenue. Will they report what they sold to distributors or will they they report what patients bought? Of course, Dara could have sold $1 million to distributors, but most will be returned to Dara when it expires.
Tamoxifen is in a class of medications called antiestrogens that block the activity of estrogen. These drugs are may stop the growth of some breast tumors that need estrogen to grow — called estrogen-positive tumors. Tamoxifen, which comes in both tablet and thanks to DARA reformulated liquid form, is used to treat breast cancer that has spread to other parts of the body in both men and women, to treat early breast cancer in women who have previously been treated for it, to reduce the risk of developing more serious types of breast cancer in some women, and to reduce the risk of breast cancer in women who are at high risk. “Earlier studies have shown that taking it for at least five years is better than taking it for just two, now it looks like taking it for even longer is even better.”
Wood, think of the millions of patients who have benefitted from the drug and family members who have loved ones live longer and shared more years together as a result of using Soltamax. Before I'd pass judgement and discard a product as a joke, why don't you walk through the hopistal cancer ward and talk to patients and get their view? Oh wait that would require both apptitude and common sense which you obviously lack either. Nuff Said.....join the ranks of Whizz and open mouth and insert foot.....
"result of using Soltamax"...You mean Tamoxifen tablets which can be purchased for around $24 for a 3 months supply at Walmart. Soltamox is liquid form and expensive and has sold poorly in the marketplace.
Anyway, Tamoxifen usefulness is also questionable. It decreases breast cancer but increase uterine cancer since Tamoxifen increases estrogen receptor activity in the uterus. So in a population of 1000, Tamoxifen might reduce breast cancer by 2 to 3 but on the flip-side the incidence of uterine cancer might increase by 2 to 3.
Your "guess" is wrong... a lot of bashers like yourself started posting yesterday around 3:30 as the share price kept growing. A lot of bashers must have noticed something they don't like so therfore post as much negativity to hopefully reverse this trend... gonna be a great day here at dara...
"started posting yesterday around 3:30"...No, I posted at 3:30AM and it is dark outside. COO, Christopher Clement, has been involved with Soltamox at Savient (2005), Oncogenerix (2011), and now Dara (2012). At Savient, he divested Rosemont Pharma to pursue Krystexxa. Looks like he made the wrong decision back then as Rosemont is now worth more than Savient which looks like it is headed for bankruptcy. So I would say Christopher Clement has a bad track record of success. Maybe he thinks third times the charm for Soltamox.